Scinai Immunotherapeutics
SCNI
11 hedge funds and large institutions have $2.27M invested in Scinai Immunotherapeutics in 2019 Q1 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
10% more funds holding
Funds holding: 10 → 11 (+1)
6% more capital invested
Capital invested by funds: $2.13M → $2.27M (+$137K)
0% less ownership
Funds ownership: 0% → 0% (-0%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EWM
Edge Wealth Management
New York
|
+$52K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$520 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mariner
Overland Park,
Kansas
|
-$129K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$10.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
II
1
Ibex Investors
Denver,
Colorado
| $1.95M | – | – | – |
|
|
BHB
2
Bank Hapoalim BM
Tel Aviv,
Israel
| $135K | – | – | – |
|
3
HighTower Advisors
Chicago,
Illinois
| $91K | – | – | – |
|
|
PVH
4
Psagot Value Holdings
Tel Aviv,
Israel
| $59K | – | – | – |
|
|
LTFS
5
Ladenburg Thalmann Financial Services
Miami,
Florida
| $14K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $5K | -$10.9K | -21 | -70% |
|
7
Royal Bank of Canada
Toronto,
Ontario, Canada
| $5K | – | – | – |
|
8
Wells Fargo
San Francisco,
California
| $5K | – | – | – |
|
9
Morgan Stanley
New York
| $3K | – | – | – |
|
|
10
Mariner
Overland Park,
Kansas
| – | -$129K | -270 | Closed |
|
|
11
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | +$520 | +1 | New |
|
|
EWM
12
Edge Wealth Management
New York
| – | +$52K | +100 | New |
|
SCNI Hedge Fund Activity: Q1 2019 in Review
11 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q1 2019, worth a combined $2.27M — up 6.4% from $2.13M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new SCNI positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Edge Wealth Management, opening a new position worth an estimated $52K. The largest seller was Mariner, exiting entirely with an estimated $129K sold.
- 11 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q1 2019, up from 10 in Q4 2018.
- Funds reported $2.27M of Scinai Immunotherapeutics stock for Q1 2019, up 6.4% quarter-over-quarter.
- 2 funds opened new Scinai Immunotherapeutics positions in Q1 2019 and 1 closed out, a net change of +1 holder.
- The largest Scinai Immunotherapeutics buyer in Q1 2019 was Edge Wealth Management, an estimated $52K added.
- The largest Scinai Immunotherapeutics seller in Q1 2019 was Mariner, an estimated $129K sold.
Based on aggregated 13F filings for Q1 2019.